Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

5.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.5K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.1K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

857
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
857
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.1K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.1K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

3.8K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.8K
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

14.4K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
14.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Review of Type 1 Diabetes-Reply.

JAMA·2026
Same author

Extended Follow-up of Type 1 Diabetes Immunotherapy Trial Participants Suggests Benign Side Effect Profile.

Diabetes care·2026
Same author

Accounting for Age-Related Increases in HbA1c More Accurately Quantifies Risk of Type 1 Diabetes Progression in Islet Autoantibody-Positive Adults.

Diabetes care·2026
Same author

Low-Dose Antithymocyte Globulin in Type 1 Diabetes: Real-World Exploratory Observation of C-Peptide by Modified Quantitative Response (mQR).

Diabetes care·2026
Same author

C-Peptide Provides Critical Contextual Insight Into Elevated Glucose Values During Progression to Type 1 Diabetes.

Diabetes care·2026
Same author

Immune Intervention and Beta Cell Replacement Therapies in T1D.

Diabetes technology & therapeutics·2026
Same journal

WHO Issues Guidelines for Treating Ebola and Marburg Viruses.

JAMA·2026
Same journal

FDA Approves Additional Naloxone Nasal Spray for Opioid Overdose.

JAMA·2026
Same journal

HIV May Hide in More Cells Than Previously Thought-Here's What That Could Mean for a Cure.

JAMA·2026
Same journal

US Dietary Supplement Use Increasing, Especially in Older Adults.

JAMA·2026
Same journal

Heat Stress From Climate Change Surges Globally.

JAMA·2026
Same journal

Strength Training Linked With Lower Cardiovascular Disease Risk in Women.

JAMA·2026
See all related articles

Related Experiment Video

Updated: Feb 17, 2026

Isolation of Human Islets from Partially Pancreatectomized Patients
11:10

Isolation of Human Islets from Partially Pancreatectomized Patients

Published on: July 30, 2011

17.0K

Type 1 Diabetes: A Review.

Laura M Jacobsen1, Desmond A Schatz1

  • 1Departments of Pediatrics and Pathology, University of Florida Diabetes Institute, University of Florida College of Medicine, Gainesville.

JAMA
|February 16, 2026
PubMed
Summary
This summary is machine-generated.

Type 1 diabetes is an autoimmune condition causing hyperglycemia and insulin deficiency, affecting millions globally. Early detection via autoantibodies and advanced insulin therapies like continuous glucose monitors improve patient outcomes.

More Related Videos

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

2.3K
Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
10:09

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

10.1K

Related Experiment Videos

Last Updated: Feb 17, 2026

Isolation of Human Islets from Partially Pancreatectomized Patients
11:10

Isolation of Human Islets from Partially Pancreatectomized Patients

Published on: July 30, 2011

17.0K
Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

2.3K
Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
10:09

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

10.1K

Area of Science:

  • Endocrinology
  • Immunology
  • Metabolic Disorders

Background:

  • Type 1 diabetes (T1D) is an autoimmune disease characterized by pancreatic beta-cell destruction, leading to insulin deficiency and hyperglycemia.
  • It accounts for 5-10% of all diabetes cases, affecting millions worldwide and causing significant microvascular and macrovascular complications.
  • The presence of specific autoantibodies, such as anti-GAD65 and anti-ZnT8, is a hallmark of T1D, often preceding clinical diagnosis.

Purpose of the Study:

  • To summarize the key aspects of Type 1 diabetes, including its definition, prevalence, diagnostic markers, and current treatment strategies.
  • To highlight the role of autoantibodies in early T1D detection and the impact of advanced insulin delivery systems on glycemic control.

Main Methods:

  • Literature review and synthesis of existing data on Type 1 diabetes epidemiology, pathophysiology, and clinical management.
  • Analysis of findings from randomized clinical trials investigating continuous glucose monitors and insulin pumps.

Main Results:

  • Type 1 diabetes is diagnosed through hyperglycemia and the presence of islet autoantibodies in 90-95% of patients.
  • Continuous glucose monitoring combined with insulin pumps significantly reduces hypoglycemia and improves HbA1c levels, especially in individuals with higher baseline levels.
  • Lifelong insulin replacement therapy remains the cornerstone of T1D management.

Conclusions:

  • Type 1 diabetes requires lifelong insulin therapy, with advanced technologies offering improved glycemic control and reduced complications.
  • Autoantibody testing is crucial for early diagnosis and differentiating T1D from other diabetes types.
  • Further research into T1D pathogenesis and novel therapeutic strategies is essential for improving patient outcomes.